Single cell RNA sequencing (scRNA-seq) data on the human CD45+ cells and tumor cells collected from four different treatment groups of hCD34+ humanized mice with human TNBC xenografic tumor model (mixed sample, non-demultiplexed)
Using a hCD34+ humanized mouse tumor model, the single-cell sequencing analysis revealed that in vivo knockdown of EPIC1 enhanced the T cells and macrophage infiltration by activating type I IFNs signaling. Overall design: To study how in vivo knockdown of EPIC1 regulates the tumor microenvironment and  pembrolizumab response, we first established a hCD34+ humanized mouse model (HuCD34-NCG mice, Charles River) with human TNBC (MDA-MB-468) xenografic tumor model. Then we performed single cell RNA sequencing (scRNA-seq) analysis on the CD45+ cells and tumor cells collected from four treatment mice groups: LNA-control + isotype control (IgG) antibody (n=1), LNA-EPIC1 + isotype control (IgG) antibody (n=1),  LNA control + human anti-PD-1 antibody pembrolizumab (Pem) (n=1), and LNA-EPIC1 + human anti-PD-1 antibody pembrolizumab (Pem) (n=2). Processed data file contents: HumanHTO3_exp_scale.csv: CD45+ cells, LNA-control + isotype control (IgG) antibody HumanHTO6_exp_scale.csv: CD45+ cells, LNA-EPIC1 + isotype control (IgG) antibody HumanHTO9_exp_scale.csv: CD45+ cells, LNA control + human anti-PD-1 antibody pembrolizumab HumanHTO12_exp_scale.csv: CD45+ cells, LNA-EPIC1 + human anti-PD-1 antibody pembrolizumab HumanHTO14_exp_scale.csv: CD45+ cells, LNA-EPIC1 + human anti-PD-1 antibody pembrolizumab